What is the first‑line pharmacologic treatment for dementia?

First-Line Pharmacologic Treatment for Dementia

Cholinesterase inhibitors—specifically donepezil, rivastigmine, or galantamine—are the first-line pharmacologic treatment for mild to moderate dementia, with drug selection based on tolerability, adverse effects, ease of use, and cost rather than superior efficacy of one agent over another. 1, 2

Initial Treatment Selection

For patients with mild to moderate Alzheimer disease or vascular dementia, start with a cholinesterase inhibitor 1, 2:

• Donepezil: Begin at 5 mg once daily with food, increase to 10 mg daily after 4–6 weeks if tolerated 3, 2
• Rivastigmine: Start at 1.5 mg twice daily with meals, increase by 1.5 mg twice daily every 4 weeks as tolerated, maximum 6 mg twice daily 3, 2
• Galantamine: Initiate at 4 mg twice daily with meals, increase to 8 mg twice daily after 4 weeks, may increase to 12 mg twice daily based on tolerability 3, 2

Avoid tacrine due to serious hepatotoxicity requiring biweekly liver monitoring. 3, 2

Expected Benefits and Realistic Expectations

The benefits of cholinesterase inhibitors are statistically significant but clinically modest 1, 2:

• Approximately 20–35% of patients achieve clinically meaningful improvement, roughly equivalent to delaying cognitive decline by one year 3
• Most patients experience stabilization or slower decline rather than improvement 3
• Treatment effects, if present, should be observed within 3 months 1, 2
• These medications do not cure dementia or reverse the underlying disease progression 1, 2

Monitoring and Assessment Timeline

Conduct comprehensive assessment at 6–12 months using 1, 3:

• Physician global clinical impression
• Caregiver reports of functional and behavioral changes
• Detailed cognitive testing (brief tools like MMSE are relatively insensitive to cholinesterase inhibitor effects) 1, 3

Continue therapy when: cognitive function stabilizes or declines more slowly than pre-treatment trajectory, and caregivers report stable or improved activities of daily living 3

Discontinue therapy when: intolerable side effects persist despite dose adjustment, decline continues at pre-treatment rate after 6–12 months, or medication adherence remains poor 1, 3

Common Adverse Effects and Management

Gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common side effects 1, 2:

• Nausea occurs approximately 2.5-fold more often than placebo 3
• Diarrhea shows a relative risk of 2.57 compared with placebo 3
• Mitigate by taking medication with food and using gradual dose titration 3
• Withdrawal due to adverse events ranges from 5–20%, comparable to placebo rates of 7–13% 1, 3

Other adverse effects include insomnia, abnormal dreams, and muscle cramps (relative risk 7.73–9.62) 3

No statistically significant difference exists between cholinesterase inhibitors and placebo for serious adverse events, aside from expected cholinergic side effects 1, 3

Moderate to Severe Dementia

For moderate to severe Alzheimer disease, memantine is indicated 1, 2:

• Standard dose: 20 mg/day (titrate by 5 mg weekly in divided doses) 3, 2
• Can be used as monotherapy or in combination with a cholinesterase inhibitor 2, 4
• Shows statistically significant but not clinically important improvement in cognition scores 1
• Adverse effects include dizziness, diarrhea, nausea, and agitation (withdrawal rates 9–12%) 1, 4

Escalation Strategy for Non-Responders

If a patient continues to decline after 3–6 months on optimized cholinesterase inhibitor monotherapy, add memantine while continuing the cholinesterase inhibitor 3:

• Combination therapy yields additional improvements of ~3.4 points on cognitive scales and ~1.4 points on activities-of-daily-living scales compared with monotherapy 3
• Switching to another cholinesterase inhibitor is reasonable only when the current medication is not tolerated; no evidence demonstrates superiority of one agent over another 1, 3

Critical Contraindications

Major contraindications include 1:

• Uncontrolled asthma
• Angle-closure glaucoma
• Sick sinus syndrome or significant bradycardia
• Left bundle-branch block
• Active peptic ulcer disease

Common Pitfalls to Avoid

• Premature discontinuation: Do not stop before 6–12 months unless side effects are intolerable 3
• Inadequate titration: Do not remain on starting doses indefinitely; attempt escalation when tolerated 3
• Over-reliance on brief cognitive tests: Use comprehensive functional and caregiver assessments rather than relying solely on MMSE scores 1, 3
• Unrealistic expectations: Address expectations before initiating treatment; stabilization or slower decline constitutes success, not reversal 3